Holen Sie sich die Stockscreener-App
1.03
5.10%
0.05
Schlusskurs vom Vortag:
$0.98
Offen:
$0.98
24-Stunden-Volumen:
54,655
Relative Volume:
3.06
Marktkapitalisierung:
$12.19M
Einnahmen:
$248.40K
Nettoeinkommen (Verlust:
$-3.05M
KGV:
-3.9448
EPS:
-0.2611
Netto-Cashflow:
$-3.30M
1W Leistung:
+5.64%
1M Leistung:
-3.29%
6M Leistung:
-21.97%
1J Leistung:
-53.18%
1-Tages-Spanne:
$0.9408
$1.05
1-Wochen-Bereich:
$0.9314
$1.05
52-Wochen-Spanne:
$0.6801
$3.68
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare GDTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.03 | 12.19M | 248.40K | -3.05M | -3.30M | -0.2611 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
GDTCCytoMed Therapeutics Ltd Options - Finviz
CytoMed, a Singapore Biotech, RevolutionizesCancer Treatment Using Donor Immune Cells - openPR.com
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank - The Globe and Mail
Form 6K CytoMed Therapeutics Ltd For: 23 June - Investing.com UK
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com - Investing.com Australia
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
CytoMed Therapeutics Ltd (GDTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Institutional Confidence - TradingKey
CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytoMed Therapeutics Ltd (GDTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals - Stock Titan
CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into FocusDouble Top - newsline.com
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares - Stock Titan
CytoMed Therapeutics LtdA Rising Star in Singapore's Cancer Biotechnology Sector - openPR.com
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News - Moomoo
CytoMed Therapeutics Limited is accelerating its international expansion - openPR.com
CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3 - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares - Stock Titan
CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase - Stock Titan
[144] CytoMed Therapeutics Ltd SEC Filing - Stock Titan
GDTC Price Today: CytoMed Therapeutics Limited Stock Price, Quote & Chart | MEXC - MEXC
TradingKey - TradingKey
CytoMed Renames Subsidiary to Drive Asian and International Expansion - TipRanks
CytoMed Therapeutics (GDTC) refocuses on Asia with new subsidiary name - Stock Titan
CytoMed Therapeutics : Audited Financial Statements for FY2025 - marketscreener.com
CytoMed (GDTC) Stock Hedge Funds (Slight Downtick) 2026-04-18PCR Mean Reversion - Newser
CytoMed (GDTC) Stock Deal Activity (Slight Rise) 2026-04-16Combination Correction - newsline.com
CytoMed Therapeutics (GDTC) 2026 AGM to vote on takeover code waiver, new share issuance - Stock Titan
GDTC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GDTC Stock Analysis: CytoMed Therapeutics Limited gains 3 percent at 1.03 mark - Xã Châu Thành
Rising R&D loss as CytoMed (NASDAQ: GDTC) advances γδ T cell therapies - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) flags losses and funding needs in 2025 report - Stock Titan
Stop Loss: Why is CytoMed Therapeutics Limited stock going upWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
AI Stocks: Can CytoMed Therapeutics Limited withstand a market correctionMarket Performance Recap & Scalable Portfolio Growth Ideas - baoquankhu1.vn
GDTC SEC FilingsCytoMed Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
GDTC Technical Analysis & ETF Price Forecast - Intellectia AI
GDTC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GDTC Should I Buy - Intellectia AI
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 1% – Still a Buy? - Defense World
Insider Sell: What analysts say about CytoMed Therapeutics Limited stock2025 Year in Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):